Blogs

Categories

Select a sub-category to view results

Icon
Films and Coatings
vail 4ml
Pharmaceutical Packaging Components
Icon
Prefillable Systems
Icon
Self Injection Devices
Icon
Vial Containment Solutions
Icon
Washing and Sterilization
Icon
Reconstitution and Transfer Devices

Select a sub-category to view results

Icon
Analytical Lab Services
Icon
Contract Manufacturing
Icon
Fill-Finish
Icon
Regulatory Support

Select a sub-category to view results

Icon
Cell and Gene Therapy Packaging
Icon
Drug Development Process
Icon
Regulatory Challenges
Icon
Transitioning to Combination Products

Select a sub-category to view results

Icon
Corporate Development
Icon
ESG/Sustainability
Icon
One West Team (Employee Culture)
Icon
Our Culture of Giving (Philanthropy)
Icon
Research and Development

Previous Blogs

Daikyo Crystal Zentih Leur Lock Syringe
Opthalmic Drug Delivery
Addressing the Complexities of Ophthalmic Drug Delivery

By Susan Dounce

May 01, 2018

Anti-VEGF therapeutics for the treatment of ophthalmic conditions such as neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) have significantly improved patient prognoses, in some cases preventing or reversing progression to blindness.  Routine injections into the eye of recombinant protein drugs such as bevacizumab, ranibizumab or aflibercept have proven to be efficacious in neutralizing the binding of over-expressed vascular endothelial growth factor (VEGF) proteins to their corresponding cellular receptors, thus interrupting the angiogenesis signaling pathway which otherwise leads to the disease states. In short, anti-VEGF injections are preventing or restoring vision loss for millions of people world-wide.

Read More